Figure 9.

Treatment with AS101 decreases very late antigen-4 (VLA-4) activity on glomerular macrophages. Rats were treated as follows: daily i.p. injection with PBS with no αGBM administration (control); daily injection with PBS of αGBM-induced rats (aGBM); daily i.p. injection with AS101 (100 μg/rat) starting 3 days after αGBM administration (AS101 (+3) + αGBM); At day 14 after αGBM administration, macrophages were isolated from glomeruli of treated rats and cultured on VCAM-1, fibronectin, or BSA-coated microwells at 10⁴/well in triplicates for 1 h. Non-attached cells were washed out and the extent of the remaining attached cells was evaluated by XTT (A). Data are presented as mean ± SE from four rats/group. ^#p < 0.01 increase vs. control; **p < 0.01 decrease vs. αGBM. The two-way ANOVA was used (A). Rats were treated with anti-glomerular basement membrane (anti-GBM) and PBS or with anti-GBM and AS101(+3). At 2 weeks after anti-GBM administration, macrophages were isolated from glomeruli of rats and evaluated for VLA-4 expression by fluorescence-activated cell sorter analysis. (B) Results show one representative experiment of four rats/group analyzed.